ESTRO 2020 Abstract book

Multimodal approach to oligometastatic breast disease: current state-of-the-art .................................................... (Abs. 260-262) The role of radiotherapy in locally advanced pancreatic cancer ................................................................................... (Abs. 263-266) How to enhance the quality of treatment planning studies .......................................................................................... (Abs. 267-269) Application of machine learning to CTV definition .......................................................................................................... (Abs. 270-272) Patient involvement in radiation oncology ...................................................................................................................... (Abs. 273-275) Poster Highlights Poster highlights 9 CL: Lung ............................................................................................................................................... (Abs. 276-282) Poster highlights 10 PH: Toxicity modelling .................................................................................................................... (Abs. 283-289) Poster discussion CL: Breast 2 ........................................................................................................................................................................... (Abs. 290-295) PH: Quantitative functional and biological imaging ........................................................................................................ (Abs. 296-300) PH: Treatment planning: applications 2 ........................................................................................................................... (Abs. 301-306) PH: Adaptive radiotherapy and inter-fraction motion management 1 ......................................................................... (Abs. 307-312) Proffered Papers Proffered papers 14: QoL and PROMs ............................................................................................................................. (Abs. 313-318) Proffered papers 15: Radiation response biomarkers ................................................................................................... (Abs. 319-324) Proffered papers 16: Breast ............................................................................................................................................... (Abs. 325-330) Proffered papers 17: GI ...................................................................................................................................................... (Abs. 331-336) Proffered papers 18: Intra-fractional motion management .......................................................................................... (Abs. 337-342) Proffered papers 19: Auto-contouring using deep learning .......................................................................................... (Abs. 343-348) Proffered papers 20: Ensuring precision and accuracy in RT ........................................................................................ (Abs. 349-354) Poster Highlights Poster highlights 11 CL : CNS ............................................................................................................................................. (Abs. 355-361) Poster highlights 12: PH Daily challenges in routine RT ................................................................................................. (Abs. 362-368) Plenary Session Clinical trials ......................................................................................................................................................................... (Abs. 369-374) Joint Symposium ESTRO-EORTC: Redefining oligometastatic disease: incorporating advanced imaging into clinical trials ............... (Abs. 375-378) Symposium Use of 3-dimensional organoid models in radiation research ...................................................................................... (Abs. 379-381) Controversies in locally advanced breast cancer ............................................................................................................ (Abs. 382-385) Second malignancy after modern radiotherapy: more or less than historical precedents ....................................... (Abs. 386-389) Radiobiological guidance for treatment planning ........................................................................................................... (Abs. 390-392) Audits for advanced radiotherapy techniques ................................................................................................................ (Abs. 393-396) Debate This house believes that RTTs will be leading ALL decision making in real-time adaptive radiation therapy in the future ......................................................................................................................................................................... (Abs. 397-398) Poster Highlights Poster highlights 13 CL : Gynaecology .............................................................................................................................. (Abs. 399-405) Poster highlights 14 PH: MRI only planning ..................................................................................................................... (Abs. 406-412) Poster discussion CL: Lung ................................................................................................................................................................................ (Abs. 413-418) CL: Upper and Lower GI 1 .................................................................................................................................................. (Abs. 419-424) PH: Radiobiological and predictive modelling, and radiomics 1 ................................................................................... (Abs. 425-430) PH: Implementation of new techniques 1 ........................................................................................................................ (Abs. 431-436) Plenary Session Highlights of Proffered papers .......................................................................................................................................... (Abs. 437-439)